Dronedarone for the treatment of atrial fibrillation: A NICE single technology appraisal

PharmacoEconomics

Volumn 30, Issue 1, 2012, Pages 35-46

  McKenna, Claire ^a   Maund, Emma ^a   Sarowar, Muhammad ^a   Fox, David ^a   Stevenson, Matt ^b   Pepper, Chris ^c   Woolacott, Nerys ^a   Palmer, Stephen ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Yorkshire Heart Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRONEDARONE; FLECAINIDE; PLACEBO; PROPAFENONE; SOTALOL;

ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STROKE; THERAPY EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG COSTS; GREAT BRITAIN; HUMANS; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 83455172444     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11594280-000000000-00000     Document Type: Review

References (21)

1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal (STA) process. London: NICE, 2006 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/STA-Process-Guide.pdf. [Accessed 2010 May 1]
2. Sculpher M. Single technology appraisal at theUKNational Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics 2010; 28 (5): 347-9
3. Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics 2010; 28 (5): 351-62
4. Bagust A, Greenhalgh J, Boland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics 2010; 28 (6): 439-48
5. Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics 2011; 29 (2): 133-40
6. Scotland G, Waugh N, Royle P, et al. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics 2011; 29 (11): 951-61
7. Dickson R, BagustA, Boland A, et al. Erlotinibmonotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics. In press
8. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a NICE single technology appraisal. Pharmacoeconomics. In press
9. Yang H, Craig D, Epstein D, et al. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics. In press
10. Boyers D, Jia X, Jenkinson D, et al. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics. In press
11. National Institute for Health and Clinical Excellence. Atrial fibrillation: dronedarone. London: NICE, 2010 [online]. Available from URL: http://guidance.nice.org.uk/TA/Wave 19/57 [Accessed 2010 Jul 16]
12. Steinberg JS. Atrial fibrillation: an emerging epidemic. Heart 2004; 90: 239-40
13. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82 (7 Suppl.): 2-9N
14. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 2010 May 1]
15. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357 (10): 987-99 (Pubitemid 47367078)
16. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360 (7): 668-78
17. Sanofi-Aventis Pharmaceuticals. Double blind trial to evaluate the efficacy and safety of dronedarone (400mg bid) versus amiodarone (600 mg daily for 28 days, then 200 mg daily thereafter) for at least 6 months for the maintenance of sinus rhythm in patients with atrial fibrillation: DIONYSOS clinical study report. Bridgewater (NJ): Sanofi- Aventis Pharmaceuticals, 2009
18. National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians, 2006 [online]. Available fromURL: http://guidance.nice.org.uk/CG36/Guidance/pdf/English [Accessed 2010May 10]
19. Datapharm Communications. Electronic medicines compendium[ online].Available fromURL: http://www.medicines.org.uk/emc [Accessed 2009 Nov 25]
20. National Institute for Health and Clinical Excellence. Atrial fibrillation - dronedarone: appraisal consultation document. London: NICE, 2009 Dec [online]. Available from URL: http://www.nice.org.uk/guidance/index.jsp? action= folder&o=46767 [Accessed 2010 May 10]
21. National Institute for Health and Clinical Excellence. Atrial fibrillation - dronedarone: final appraisal determination. London: NICE, 2010 Jul [online]. Available from URL: http://guidance.nice.org.uk/TA/Wave19/57/FAD [Accessed 2010 Jul 16]